Avenda Health, a Culver City, CA-based AI healthcare company, raised $10M in Series B funding.
The round was led by VCapital with participation from Plug & Play Ventures and Wealthing VC Club.
The company intends to use the funds to accelerate the use of iQuest, an AI-enabled patient management software that identifies and visualizes a patient’s prostate cancer, and to continue clinical evidence development.
Led by CEO Shyam Natarajan, Avenda Health is creating a more personalized future of prostate cancer care. Using deep learning, its software platform maps a patient’s cancer in 3D, giving physicians precise information and the confidence to make care decisions.
The FocalPoint System powered by iQuest provides a system to treat prostate cancer in-office under ultrasound guidance while preserving quality of life. The system spares healthy tissue by targeting only the tumor, which minimizes side effects, and uses patient-specific information and AI to deliver a precise and personalized treatment. To predict the extent of disease and support decision-making in cancer care, Avenda Health developed iQuest, which uses AI-deep learning to uncover cancer previously hidden within traditional MRI mapping and can be used by physicians to better plan treatments.
FocalPoint is FDA cleared for soft tissue ablation. iQuest and its use with FocalPoint are not FDA cleared and are for investigational use only.
FinSMEs
26/08/2022